|
www.Xtremepicks.Com: Xtremepicks Alerts November 24, 2009 : MDNU, KERX, CMTL and GIVN
(M2 PressWIRE Via Acquire Media NewsEdge) Xtremepicks.com Alerts include Medical Nutrition USA, Inc. (NASDAQ: MDNU), Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), Comtech Telecommunications Corp. (Nasdaq: CMTL) and Given Imaging Ltd. (NASDAQ: GIVN)
Medical Nutrition USA, Inc. (NASDAQ: MDNU) trading at $2.09 per share on trading volume of 2,211 shares.
In a press release out on November 24, Medical Nutrition USA Introduces Diff-Stat(TM) to Combat Antibiotic-Associated Intestinal Maladies
New Product Addresses Serious Health Risks
ENGLEWOOD, NJ, Nov 24, 2009 -- Medical Nutrition USA, Inc. (NASDAQ: MDNU), a developer and distributor of uniquely engineered, nutrition-medicine products, announced the introduction of Diff-Stat(TM), a new supplement containing pre- and probiotics to help restore and maintain beneficial bacteria that prevent the onset of antibiotic-associated diarrhea (AAD) and clostridium difficile (C-diff).
About Medical Nutrition USA, Inc.
Medical Nutrition USA develops and distributes products for the nutritionally at risk who are under medical supervision. Its products are used primarily in long-term care facilities, hospitals, dialysis clinics and bariatric clinics. The Company's product lines include Pro-Stat(R), Fiber-Stat(R) and UTI-Stat(TM), as well as private label products. Additional information is available atwww.mdnu.com.
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) trading at $2.29 per share on trading volume of 172,651 shares.
In a press release out on November 24, Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
--Presentation Scheduled for Wednesday, December 2nd at 10:30AM ET
NEW YORK, Nov 24, 2009 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Piper Jaffray 21st Annual Health Care Conference being held in New York City.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.
Comtech Telecommunications Corp. (Nasdaq:CMTL) trading at $29.80 on a volume of 104,130 shares
In a press release out on November 24, Comtech Telecommunications Corp. Wins $2.4 Million in SATCOM Equipment Orders to Support Military Communications
MELVILLE, N.Y., Nov 24, 2009 -- Comtech Telecommunications Corp. (Nasdaq:CMTL) announced today that its Tempe, Arizona-based subsidiary, Comtech EF Data Corp., received $2.4 million in orders for satellite modems and redundancy switches. The equipment will be employed by the United States government to support an ongoing military communications program.
Comtech Telecommunications Corp. designs, develops, produces and markets innovative products, systems and services for advanced communications solutions. The Company believes many of its solutions play a vital role in providing or enhancing communication capabilities when terrestrial communications infrastructure is unavailable, inefficient or too expensive. The Company conducts business through three complementary segments: telecommunications transmission, mobile data communications and RF microwave amplifiers. The Company sells products to a diverse customer base in the global commercial and government communications markets. The Company believes it is a market leader in the market segments that it serves.
Given Imaging Ltd. (NASDAQ: GIVN) trading at $17.65 on a volume of 95,737 shares
In a press release out on November 24, Given Imaging Announces RAPID(R) pH Software for Bravo(R) pH Monitoring System
LONDON, Nov 24, 2009 -- Given Imaging Ltd. (NASDAQ: GIVN), the global leader in patient-friendly GI diagnostic and monitoring solutions, today unveiled RAPID(R) pH review and analysis software for the Bravo(R) pH Monitoring System. This all-new software was designed to streamline pH monitoring workflow through simplified, easy-to-use screen layouts and intuitive software navigation. RAPID pH replaces the software previously associated with the Bravo pH Monitoring System, which was acquired in December 2008. RAPID pH can be viewed at the Company's booth # 83 at the Gastro 2009 conference taking place in London from November 21 to 25.
About Given Imaging Ltd.
Since 2001, Given Imaging has advanced gastrointestinal diagnosis by developing innovative, patient-friendly tools based on its PillCam(R) Platform. PillCam capsule endoscopy provides physicians with natural images of the small intestine via PillCam SB, the esophagus through PillCam ESO and the colon with PillCam COLON [not cleared for use in the USA]. The PillCam capsules are miniature video cameras that patients ingest. Given Imaging's other capsule products include Agile(TM) patency capsule, to verify intestinal patency, and Bravo(R), the only wireless, catheter-free, 48-hour pH test commercially available for pH testing to assess gastroesophageal reflux disease (GERD). Given Imaging's products use cutting-edge, wireless technology and advanced software to enable gastroenterologists to better diagnose diseases of the esophagus, small bowel and colon [PillCam COLON is not cleared for use in the USA.] and more accurately treat patients. All Given Imaging products allow patients to maintain normal activities. Given Imaging's headquarters, manufacturing and R&D facilities are located in Yoqneam, Israel, with operating subsidiaries in the United States, Germany, France, Japan, Australia and Singapore. For more information, please visit http://www.givenimaging.com.
Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.
Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ Back To Contact Center Solutions Homepage's Homepage ]
|
NextiraOne Obtains Cisco's Unified Contact Centre Enterprise ATP Status 
BT expands further in high growth regions; Investment in people, infrastructure, network and services to help customers expand in Turkey, the Middle East and Africa
NEW Consolidating Infrastructures: IT's New Call to Business [white paper]
